In 1998 he joined the group of Professor Norbert Haider, at the Institute of Pharmaceutical Chemistry of the University of Wien (Austria), as a predoctoral researcher.
During 2000–2003 he was co-leader of the chemistry team of an academic-industrial project aimed at the development of novel asthmatic agents.
In 2004 Eddy moved to the Department of Medicinal Chemistry at the University of Bari (Italy) to join the group of Professor Angelo Carotti as a postdoctoral research associate. During his stay in Bari, Eddy developed kinase inhibitors with anticancer activity and β-amyloid aggregation inhibitors for Alzheimer disease.
In 2006 Eddy began his independent research career after being awarded a Parga Pondal Research Fellow at the Instituto de Farmacia Industrial (IFI) of the University of Santiago de Compostela. In 2008 he founded the ComBioMed Group, a technological platform that exploits the advantages of multicomponent reactions in industrial-based drug discovery programs.
Since 2011 he has been an associate professor (Senior Lecturer) of Organic Chemistry & Medicinal Chemistry at the Faculty of Pharmacy of the University of Santiago de Compostela. Eddy joined the CIQUS as a group leader in 2011 and obtained the Spanish habilitation to full Professor in 2019. In 2015 he was awarded the prestigious Salvador de Madariaga Research Fellowship and was a visiting professor for six months in the group of Professor David Spring (Cambridge University).
Since April 2023 Eddy is Full Professor of Medicinal Chemistry.
Eddy has published over 90 papers, with more than 50 as a senior author, and has four patents. His publications have been cited ~2000 times and this corresponds to an overall h-index of 26. He has been the principal investigator on eight public research projects and 16 collaborative research contracts with companies such as Oryzon Genomics, Oncostellae and Landsteiner Genmed.
Eddy´s research programs are focused on the Medicinal Chemistry and Chemical Biology of GPCRs. His group is involved in discovering novel drugs and molecular probes that target GPCRs, with an emphasis on contemporary GPCR concepts (e.g., oligomerization, biased signaling and allosteric modulation) by employing high-throughput synthetic methodologies and novel 3D printed heterogeneous catalytic systems.